Presentation by Professor Caroline Hastings, MD, Chair of the Phase 3 Trappsol® Cyclo™ Program Steering Committee and the Global Principal Investigator for the Company’s ongoing TransportNPC™ study evaluating Trappsol® Cyclo™ for the treatment of Niemann-Pick Disease Type C (NPC) (businesswire June 21, 2022)
Professor Caroline Hastings, MD will present at the 2022 NPC Conference hosted by the Australian NPC Disease Foundation being held virtually June 23-24, 2022. The title of her presentation: Intravenous Trappsol® Cyclo ™ in patients with Niemann Pick Disease type C1: Updates on the Results from Phase I and Phase I/II studies and launch of the international Phase III pivotal Transport NPC trial
Australian NPC Disease Foundation Inc (ANPDF)
Founded in 2009 by an Aussie mum with two recently diagnosed boys, this volunteer-powered charity organisation is the culmination of parents trying to save their children from an incurable and fatal disease. The ANPDF is a not-for-profit organisation that aims to support those left in the gap, raising awareness and funding research to slow or halt the progression of Niemann-Pick disease type C.
About Cyclo Therapeutics
Cyclo Therapeutics, Inc. is a clinical-stage biotechnology company dedicated to developing life-changing medicines through science and innovation for patients and families suffering from disease. The Company’s Trappsol® Cyclo™, an orphan drug designated product in the United States and Europe, is being studied in a Phase 3 pivotal clinical trial for Niemann-Pick Disease Type C, a rare and fatal genetic disease, (https://www.clinicaltrials.gov/ NCT02939547, NCT02912793, NCT03893071 and NCT04860960). The Company is planning a Phase 2 clinical trial using Trappsol® Cyclo™ intravenously in Alzheimer’s Disease based on encouraging data from an Expanded Access program for late-onset Alzheimer’s Disease (NCT03624842). Additional indications for the active ingredient in Trappsol® Cyclo™ are in development. For additional information, visit the Company’s website: www.cyclotherapeutics.com.